These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 14733726)
1. An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody. Axtelle T; Pribble J J Endotoxin Res; 2003; 9(6):385-9. PubMed ID: 14733726 [TBL] [Abstract][Full Text] [Related]
2. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. Axtelle T; Pribble J J Endotoxin Res; 2001; 7(4):310-4. PubMed ID: 11717588 [TBL] [Abstract][Full Text] [Related]
3. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Reinhart K; Glück T; Ligtenberg J; Tschaikowsky K; Bruining A; Bakker J; Opal S; Moldawer LL; Axtelle T; Turner T; Souza S; Pribble J Crit Care Med; 2004 May; 32(5):1100-8. PubMed ID: 15190957 [TBL] [Abstract][Full Text] [Related]
4. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. Verbon A; Meijers JC; Spek CA; Hack CE; Pribble JP; Turner T; Dekkers PE; Axtelle T; Levi M; van Deventer SJ; Reitsma PH; van der Poll T J Infect Dis; 2003 Jan; 187(1):55-61. PubMed ID: 12508146 [TBL] [Abstract][Full Text] [Related]
5. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. Verbon A; Dekkers PE; ten Hove T; Hack CE; Pribble JP; Turner T; Souza S; Axtelle T; Hoek FJ; van Deventer SJ; van der Poll T J Immunol; 2001 Mar; 166(5):3599-605. PubMed ID: 11207321 [TBL] [Abstract][Full Text] [Related]
6. Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia. Olszyna DP; Verbon A; Pribble JP; Turner T; Axtelle T; van Deventer SJ; van der Poll T Eur Cytokine Netw; 2003; 14(3):158-62. PubMed ID: 14656690 [TBL] [Abstract][Full Text] [Related]
7. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Opal SM; Palardy JE; Parejo N; Jasman RL Crit Care Med; 2003 Mar; 31(3):929-32. PubMed ID: 12627007 [TBL] [Abstract][Full Text] [Related]
8. CD14 expression in the first 24h of sepsis: effect of -260C>T CD14 SNP. de Aguiar BB; Girardi I; Paskulin DD; de Franca E; Dornelles C; Dias FS; Bonorino C; Alho CS Immunol Invest; 2008; 37(8):752-69. PubMed ID: 18991094 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models. Nakamura M; Takeuchi T; Kawahara T; Hirose J; Nakayama K; Hosaka Y; Furusako S Eur J Pharmacol; 2017 May; 802():60-68. PubMed ID: 28249709 [TBL] [Abstract][Full Text] [Related]
10. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932 [TBL] [Abstract][Full Text] [Related]
12. Systemic and local high mobility group box 1 concentrations during severe infection. van Zoelen MA; Laterre PF; van Veen SQ; van Till JW; Wittebole X; Bresser P; Tanck MW; Dugernier T; Ishizaka A; Boermeester MA; van der Poll T Crit Care Med; 2007 Dec; 35(12):2799-804. PubMed ID: 17901841 [TBL] [Abstract][Full Text] [Related]
13. Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens. Skinner NA; MacIsaac CM; Hamilton JA; Visvanathan K Clin Exp Immunol; 2005 Aug; 141(2):270-8. PubMed ID: 15996191 [TBL] [Abstract][Full Text] [Related]
14. Detection of circulating lipopolysaccharide-bound monocytes in children with gram-negative sepsis. Takeshita S; Nakatani K; Tsujimoto H; Kawamura Y; Sekine I J Infect Dis; 2000 Nov; 182(5):1549-52. PubMed ID: 11015235 [TBL] [Abstract][Full Text] [Related]
15. The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Kalil AC; Sun J; Florescu DF Crit Care Med; 2010 Oct; 38(10 Suppl):S663-7. PubMed ID: 21164412 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J; Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145 [TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Orfanos SE; Kotanidou A; Glynos C; Athanasiou C; Tsigkos S; Dimopoulou I; Sotiropoulou C; Zakynthinos S; Armaganidis A; Papapetropoulos A; Roussos C Crit Care Med; 2007 Jan; 35(1):199-206. PubMed ID: 17110873 [TBL] [Abstract][Full Text] [Related]
18. Spare CD14 molecules on human monocytes enhance the sensitivity for low LPS concentrations. Antal-Szalmás P; Poppelier MJ; Sümegi A; van der Bruggen T; Verhoef J; van Kessel KP; van Strijp JA Immunol Lett; 2004 Apr; 93(1):11-5. PubMed ID: 15134893 [TBL] [Abstract][Full Text] [Related]
19. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis. Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557 [TBL] [Abstract][Full Text] [Related]
20. Differential toll-like receptor expression after ex vivo lipopolysaccharide exposure in patients with sepsis and following surgical stress. Tsujimoto H; Ono S; Majima T; Efron PA; Kinoshita M; Hiraide H; Moldawer LL; Mochizuki H Clin Immunol; 2006 May; 119(2):180-7. PubMed ID: 16517212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]